133 related articles for article (PubMed ID: 8786198)
1. 72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and Serological study.
De Nictolis M; Garbisa S; Lucarini G; Goteri G; Masiero L; Ciavattini A; Garzetti GG; Stetler-Stevenson WG; Fabris G; Biagini G; Prat J
Int J Gynecol Pathol; 1996 Apr; 15(2):102-9. PubMed ID: 8786198
[TBL] [Abstract][Full Text] [Related]
2. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
3. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de e Nictolis M; Garbisa S; Masiero L; Romanini C; Graziella B
Anticancer Res; 1995; 15(6B):2799-804. PubMed ID: 8669868
[TBL] [Abstract][Full Text] [Related]
4. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis.
Zeng ZS; Cohen AM; Guillem JG
Carcinogenesis; 1999 May; 20(5):749-55. PubMed ID: 10334190
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines.
Afzal S; Lalani el-N ; Foulkes WD; Boyce B; Tickle S; Cardillo MR; Baker T; Pignatelli M; Stamp GW
Lab Invest; 1996 Feb; 74(2):406-21. PubMed ID: 8780160
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary.
Campo E; Merino MJ; Tavassoli FA; Charonis AS; Stetler-Stevenson WG; Liotta LA
Am J Surg Pathol; 1992 May; 16(5):500-7. PubMed ID: 1318001
[TBL] [Abstract][Full Text] [Related]
7. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
8. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
[TBL] [Abstract][Full Text] [Related]
9. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
10. Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors.
Autio-Harmainen H; Karttunen T; Hurskainen T; Höyhtyä M; Kauppila A; Tryggvason K
Lab Invest; 1993 Sep; 69(3):312-21. PubMed ID: 8377473
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
[TBL] [Abstract][Full Text] [Related]
12. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
13. 92K-GL (MMP-9) and 72K-GL (MMP-2) are produced in vivo by human oral squamous cell carcinomas and can enhance FIB-CL (MMP-1) activity in vitro.
Pickett KL; Harber GJ; DeCarlo AA; Louis P; Shaneyfelt S; Windsor LJ; Bodden MK
J Dent Res; 1999 Jul; 78(7):1354-61. PubMed ID: 10403463
[TBL] [Abstract][Full Text] [Related]
14. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts.
Afzal S; Lalani EN; Poulsom R; Stubbs A; Rowlinson G; Sato H; Seiki M; Stamp GW
Hum Pathol; 1998 Feb; 29(2):155-65. PubMed ID: 9490275
[TBL] [Abstract][Full Text] [Related]
15. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
[TBL] [Abstract][Full Text] [Related]
17. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
Pan Y; Jiao J; Zhou C; Cheng Q; Hu Y; Chen H
Pathobiology; 2010; 77(6):283-8. PubMed ID: 21266826
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometry and AgNORs in benign, borderline, and malignant mucinous and serous tumours of the ovary.
Griffiths AP; Cross D; Kingston RE; Harkin P; Wells M; Quirke P
Int J Gynecol Pathol; 1993 Oct; 12(4):307-14. PubMed ID: 8253547
[TBL] [Abstract][Full Text] [Related]
19. Secretion of matrix metalloproteinase-2 (72 kD gelatinase/type IV collagenase = gelatinase A) by malignant human glioma cell lines: implications for the growth and cellular invasion of the extracellular matrix.
Nakagawa T; Kubota T; Kabuto M; Fujimoto N; Okada Y
J Neurooncol; 1996 Apr; 28(1):13-24. PubMed ID: 8740587
[TBL] [Abstract][Full Text] [Related]
20. Epithelial markers to detect occult microinvasion in serous ovarian tumors.
Hanselaar AG; Vooijs GP; Mayall B; Ras-Zeijlmans GJ; Chadha-Ajwani S
Int J Gynecol Pathol; 1993 Jan; 12(1):20-7. PubMed ID: 7678103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]